Amgen's Prolia (Denosumab) ranked first in the osteoporosis treatment market. Amgen's Evenity (Romosozumab) is expected to start earning sales this year. Amgen, which has established a lineup leading to Evenity-Prolia in the osteoporosis treatment market, is expected to sustain high sales for some time. Most of the bisphosphonates, which had previously led the market, declined after the launch of Prolia.

◆Prolia's sales increased 59% in one year from ₩47.3 billion to ₩75.1 billion

According to IQVIA on the 23rd, Prolia's sales last year amounted to ₩75.1 billion. Compared to ₩47.3 billion in 2019, it increased by 59%.

Amgen released Prolia in